PI3K/AKT-IN-1, with the CAS number 3033069-84-7, is a small molecule inhibitor that specifically targets the phosphoinositide 3-kinase (PI3K) and AKT signaling pathways, which are crucial in regulating various cellular processes, including growth, proliferation, and survival. This compound is primarily studied for its potential therapeutic applications in cancer treatment, as aberrations in the PI3K/AKT pathway are commonly associated with tumorigenesis and cancer progression. The substance is characterized by its ability to selectively inhibit specific isoforms of PI3K, thereby disrupting the downstream signaling that promotes cancer cell survival and proliferation. In terms of its chemical properties, PI3K/AKT-IN-1 is typically characterized by its molecular weight, solubility, and stability under physiological conditions, which are important for its efficacy and bioavailability in therapeutic applications. Research continues to explore its pharmacokinetics, potential side effects, and effectiveness in various cancer models, contributing to the understanding of targeted cancer therapies.

PI3K/AKT-IN-1

3033069-84-7: PI3K/AKT-IN-1, with the CAS number 3033069-84-7, is a small molecule inhibitor that specifically targets the phosphoinositide 3-kinase (PI3K) and AKT signaling pathways, which are crucial in regulating various cellular processes, including growth, proliferation, and survival. This compound is primarily studied for its potential therapeutic applications in cancer treatment, as aberrations in the PI3K/AKT pathway are commonly associated with tumorigenesis and cancer progression. The substance is characterized by its ability to selectively inhibit specific isoforms of PI3K, thereby disrupting the downstream signaling that promotes cancer cell survival and proliferation. In terms of its chemical properties, PI3K/AKT-IN-1 is typically characterized by its molecular weight, solubility, and stability under physiological conditions, which are important for its efficacy and bioavailability in therapeutic applications. Research continues to explore its pharmacokinetics, potential side effects, and effectiveness in various cancer models, contributing to the understanding of targeted cancer therapies.

PI3K/AKT-IN-1 is a dual inhibitor of PI3K and AKT with anti-cancer activity, inhibiting the PI3K/AKT pathway and inducing caspase 3-dependent apoptosis.

CAS 3033069-84-7

PI3K/AKT-IN-1

PI3K/AKT-IN-1

Ref: TM-T62997